Delving into the Latest Updates on Shandong Hengli Medicine Science & Technology Co., Ltd. with Synapse

Overview

Tags

Urogenital Diseases

Other Diseases

Infectious Diseases

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	3
Chemical drugs	2

Top 5 Target	Count

LpxC(UDP-3-O-acyl-N-acetylglucosamine deacetylase)	1
MR(Mineralocorticoid receptor)	1
PDGFRs x RET x c-Kit	1

Primary objective: To evaluate the safety, tolerability and pharmacokinetic (PK) characteristics of KBP-5074 after a single oral administration. Secondary objective: To evaluate the effect of food on the PK of KBP-5074 and to explore the pharmacokinetic/pharmacodynamic (PK/PD) (plasma aldosterone) relationship.

Start Date10 Jun 2019

Sponsor / Collaborator

Shandong Hengli Medicine Science & Technology Co., Ltd.

100 Clinical Results associated with Shandong Hengli Medicine Science & Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shandong Hengli Medicine Science & Technology Co., Ltd.

Login to view more data

100 Deals associated with Shandong Hengli Medicine Science & Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shandong Hengli Medicine Science & Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

1

Phase 3

Other

9

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

KBP-7018 ( PDGFRs x RET x c-Kit )	Fibrosis More	Preclinical
KBP-8107	Glomerulosclerosis, Focal Segmental More	Preclinical
KBP-7909 ( LpxC )	Gram-Negative Bacterial Infections More	Preclinical
KBP-8044	Renal fibrosis More	Preclinical
Ocedurenone ( MR )	Hypertension More	Discontinued